Latest California Healthline Stories
The polarizing abortion issue threatens to tie up Congress, the Supreme Court and the states for the coming year. Meanwhile, Congress kicks the can down the road to December on settling its spending priorities. Joanne Kenen of Politico and the Johns Hopkins School of Public Health, Yasmeen Abutaleb of The Washington Post and Sarah Karlin-Smith of the Pink Sheet join KHN’s Julie Rovner to discuss these issues and more.
Also this week, Rovner interviews KHN’s Aneri Pattani, who delivered the latest KHN-NPR “Bill of the Month” episode about a covid test that cost as much as a luxury car.
Dr. Francis Collins, who announced he is stepping down as chief of the National Institutes of Health, used his communication skills and political insights to help protect the highly acclaimed federal research institutes through difficult times.
KHN’s Sarah Jane Tribble and Arthur Allen join Science Friday host Ira Flatow to recap the evolving news in the run-up to offering booster shots for the covid vaccine.
With real-time data streaming in from highly specialized researchers in the U.S. and abroad, NIH scientists became convinced that boosting the covid-19 vaccine was needed to save lives, prompting the president to announce a plan with a Sept. 20 start date. Scientists at the regulatory agencies weren’t yet convinced. A meeting Friday will determine what happens next. Here’s the story from behind the scenes.
A raft of startups are charging consumers hundreds of dollars to analyze the microbes in their gut and offer dietary advice based on the results. But scientists say scant research has been done, and as customers of one company have learned the hard way, the experience isn’t always smooth.
Aduhelm, approved by the Food and Drug Administration last month despite questions about its efficacy, could be prescribed to at least 1 million patients a year, for a price tag of about $56 billion. Experts suggest there might be better ways to spend that money.
Exclusive: The head of the National Institute of Allergy and Infectious Diseases says health workers ‘have lived up to the oath they take’ but says shortages of protective gear have contributed to excess deaths.
Philanthropies are funding studies of cheap, existing medications like the antidepressant fluvoxamine as covid treatments. But early hype about hydroxychloroquine and other repurposed drugs leaves researchers leery of hasty conclusions.
Hay medicamentos aprobados hace años que podrían investigarse en profundidad para tratar covid. Pero no hay interés porque no generarían grandes ganancias.
Scientists learned the wrong lesson from past outbreaks, but Dr. Anthony Fauci doesn’t cast blame.